Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05816395 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of RHH646 for Knee Osteoarthritis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT05816395 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 82 participants.
The verdict
NCT05816395, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the articular cartilage-regenerating capacity of RHH646 in the knee as well as to assess safety and tolerability in participants with knee osteoarthritis.
Interventions
- DRUG Placebo
- DRUG RHH646
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05816395
The ClinicalTrials.gov registry entry for NCT05816395 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05816395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05816395 about?
NCT05816395 is a clinical study titled "Safety and Efficacy of RHH646 for Knee Osteoarthritis". The purpose of this study was to evaluate the articular cartilage-regenerating capacity of RHH646 in the knee as well as to assess safety and tolerability in participants with knee osteoarthritis.
What is the current status of trial NCT05816395?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2023-05-31. Estimated completion is 2025-02-24.
What interventions are being tested in trial NCT05816395?
The interventions under investigation include: Placebo (DRUG), RHH646 (DRUG).
Who is sponsoring clinical trial NCT05816395?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.